Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PERSERIS ®safely and effectively. See full prescribing information for PERSERIS. PERSERIS (risperidone) for extended-release injectable suspension, for subcutaneous use. Initial U.S. Approval: 1993
Medication labelWhy this: Advisory · dailymed-prescription
PERSERIS is indicated for the treatment of schizophrenia in adults [see Clinical Studies ( 14)] .
- generic_name
- risperidone
- brand_name
- Poly(DL-lactic-co-glycolic acid), (50:50; 46000 MW), Methylpyrrolidone, Poly DL-lactic-co-glycolic acid, 50:50; 46000 MW, Methylpyrrolidone
- product_names
- Risperidone, Poly(DL-lactic-co-glycolic acid), (50:50; 46000 MW), Methylpyrrolidone, Poly DL-lactic-co-glycolic acid, 50:50; 46000 MW, Methylpyrrolidone
- ndc
- 12496-0090, 12496-0120, 12496-0090-1, 12496-0090-9, 12496-0090-5, 12496-0090-2, 12496-0589, 12496-0589-5, 12496-0589-2, 12496-0120-1, 12496-0120-9, 12496-0120-5, 12496-0120-2, 12496-0776, 12496-0776-5, 12496-0776-2
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en